Melanoma News and Research

Latest Melanoma News and Research

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

3 Jun 2014

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology.

3 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis announced today the results of a pivotal Phase II trial demonstrating that patients with locally advanced (laBCC) or metastatic basal cell carcinoma (mBCC) taking the investigational oral compound LDE225 (sonidegib) had marked and sustained tumor shrinkage after a median follow-up of 13.9 months.

2 Jun 2014

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Myriad Genetics, Inc. today presented several clinical studies on the Myriad myRisk- Hereditary Cancer test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

2 Jun 2014

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Myriad Genetics, Inc. today presented results from a pivotal clinical validation study of the Myriad myPath- Melanoma test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Ill.

2 Jun 2014

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

Researchers identify new therapeutic target for treating most common form of eye cancer

Researchers at the University of California, San Diego School of Medicine have identified a therapeutic target for treating the most common form of eye cancer in adults. They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA-approved drug.

30 May 2014

Rare type of melanoma that attacks palms, soles twice likely to recur, says NYU study

A rare type of melanoma that disproportionately attacks the palms and soles and under the nails of Asians, African-Americans, and Hispanics, who all generally have darker skins, and is not caused by sun exposure, is almost twice as likely to recur than other similar types of skin cancer, according to results of a study in 244 patients.

30 May 2014

Reduced glomerular filtration rate is independent risk factor for renal and urothelial cancer

Researchers who investigated the level of kidney function and subsequent cancer risk in more than one million adults have found that reduced glomerular filtration rate (GFR) — a key measure of reduced kidney function and chronic kidney disease (CKD) — is an independent risk factor for renal and urothelial cancer but not other cancer types.

30 May 2014

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

MedPage Today, a property of Everyday Health, Inc. and CollabRx, Inc. announced today the introduction of a new physician resource, CancerRx,™ an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.

28 May 2014

State highlights: Calif. tables immigrant health care bill; new La. hospital financing plan; Calif. insurance commissioner powers

Nearly 200 proposals were shelved in the Legislature on Friday, including controversial measures that would have provided health care coverage to people in the country illegally, imposed a tax on oil drilled from the ground and created a voluntary substance-abuse counseling program for doctors (McGreevy and Mason, 5/23).

28 May 2014

Socioeconomic status appears to influence type of cancer a person may develop

A new analysis has found that certain cancers are more concentrated in areas with high poverty, while other cancers arise more often in wealthy regions. Also, areas with higher poverty had lower cancer incidence and higher mortality than areas with lower poverty.

28 May 2014

Biologists show bioelectrical signals control tumors arising from cancer-causing genes, fatty acid

Developmental biologists at Tufts University, using a tadpole model, have shown that bioelectrical signals from distant cells control the incidence of tumors arising from cancer-causing genes and that this process is impacted by levels of a common fatty acid produced by bacteria found in the tadpole and also in humans.

28 May 2014

New analysis finds that certain cancers are more concentrated in areas with high poverty

28 May 2014

International study provides hope to patients with advanced prostate cancer

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer.

26 May 2014

Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells

Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published online by Nature Medicine.

26 May 2014

Research validates family history screening questionnaire as tool to cover multiple conditions

The family history screening questionnaire can be used to provide insight into people's susceptibility to breast, ovarian, bowel and prostate cancer, melanoma, ischaemic heart disease and type 2 diabetes.

22 May 2014

Melanoma News and Research

Latest Melanoma News and Research

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Eventual drug resistance prevents long-term cure in most patients with metastatic melanoma

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Researchers identify new therapeutic target for treating most common form of eye cancer

Rare type of melanoma that attacks palms, soles twice likely to recur, says NYU study

Reduced glomerular filtration rate is independent risk factor for renal and urothelial cancer

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

State highlights: Calif. tables immigrant health care bill; new La. hospital financing plan; Calif. insurance commissioner powers

Socioeconomic status appears to influence type of cancer a person may develop

Biologists show bioelectrical signals control tumors arising from cancer-causing genes, fatty acid

New analysis finds that certain cancers are more concentrated in areas with high poverty

International study provides hope to patients with advanced prostate cancer

Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells

Research validates family history screening questionnaire as tool to cover multiple conditions

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in